Alan Eisenberg joined Samsara Biocapital as a venture partner in 2024. An executive with over 20 years’ experience in biotech, Eisenberg works with our portfolio companies on program and commercialization strategies, with a focus on market access, reimbursement, and regulatory matters.
Previously, Eisenberg was Vice President, Global Public Policy & Government Relations at Alnylam. His responsibilities included Alnylam’s innovative strategies for access and value-based agreements with public payers, public policy and government relations, price reporting, as well as patient foundations. Prior to Alnylam, Eisenberg led government relations for Celgene and spent nearly a decade as Executive Vice President at the Biotechnology Innovation Organization (BIO).
Eisenberg served in a variety of senior policy making roles on Capitol Hill. He was an author of the Average Sales Price (ASP) methodology used in Medicare Part B reimbursement and a member of teams responsible for key health laws including Medicare Part D, as well as PDUFA III.
Earlier in his career, Eisenberg worked at Ford Motor Company as an economist and finance manager. He has a Masters in Public Policy (Harvard University), Masters in Finance (George Washington University), and a Bachelors in Science (Union College).